RT Journal Article
SR Electronic
T1 AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.30.21262666
DO 10.1101/2021.08.30.21262666
A1 Loo, Yueh-Ming
A1 McTamney, Patrick M.
A1 Arends, Rosalinda H.
A1 Gasser, Robert A.
A1 Abram, Michael E.
A1 Aksyuk, Anastasia
A1 Diallo, Seme
A1 Flores, Daniel J.
A1 Kelly, Elizabeth J.
A1 Ren, Kuishu
A1 Roque, Richard
A1 Rosenthal, Kim
A1 Streicher, Katie
A1 Tuffy, Kevin M.
A1 Bond, Nicholas J.
A1 Cornwell, Owen
A1 Bouquet, Jerome
A1 Cheng, Lily I.
A1 Dunyak, James
A1 Huang, Yue
A1 Rosenbaum, Anton I.
A1 Andersen, Hanne
A1 Carnahan, Robert H.
A1 Crowe, James E.
A1 Kuehne, Ana I.
A1 Herbert, Andrew S.
A1 Dye, John M.
A1 Bright, Helen
A1 Kallewaard, Nicole L.
A1 Pangalos, Menelas N.
A1 Esser, Mark T.
YR 2021
UL http://medrxiv.org/content/early/2021/09/08/2021.08.30.21262666.abstract
AB Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19, and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct non-overlapping epitopes on the spike protein receptor binding domain to potently neutralize SARS-CoV-2. Initially isolated from individuals with prior SARS-CoV-2 infection, the two mAbs were designed to extend their half-lives and abrogate effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-converting enzyme 2 receptor, blocking virus cell entry. Together, these two mAbs create a higher barrier to viral escape and a wider breadth of coverage, neutralizing all known SARS-CoV-2 variants of concern. In a non-human primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration prevented infection, while therapeutic administration accelerated virus clearance from lung. In an ongoing Phase I study in healthy participants (NCT04507256), 300 mg intramuscular AZD7442 provided SARS-CoV-2 serum geometric mean neutralizing titers >10-fold above those of convalescent sera for ≥3 months, which remained 3-fold above those of convalescent sera 9 months post-AZD7442 administration. Approximately 1–2% of serum AZD7442 levels were detected in nasal mucosa, a site of SARS-CoV-2 infection. Extrapolation of the time course of serum AZD7442 concentrations suggests AZD7442 may provide up to 12 months of protection and benefit individuals at high-risk of COVID-19.Competing Interest StatementYML, RHA, RAG, MEA, AA, SD, DJF, EJK, KRe, RR, KRo, KS, KMT, NJB, JB, LIC, YH, AIR, MNP and MTE are employees of, and hold or may hold stock in, AstraZeneca. PMM, OC, JD, HB and NLK were employees of AstraZeneca at the time of this study. NLK is currently an employee of and holds stock options of Eli Lilly. HA, AIK, ASH and JMD have no conflicts to declare. JEC is a recipient of the 2019 Future Insight Prize from Merck KGaA, which supported part of this work with a grant; has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines; is the founder of IDBiologics; and has received sponsored research agreements from Takeda Vaccines, IDBiologics and AstraZeneca. Clinical TrialNCT04507256Funding StatementThis study was supported by AstraZeneca.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London-Riverside Research Ethics Committee, Chelsea and Westminster Hospital, London (date of approval 17 August 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData underlying the findings described in this manuscript may be requested in accordance with AstraZenecas data sharing policy described at https://astrazenecagroup-dt.pharmacm.com/DT/Home.